Publication: Pharmacokinetics of Colistin Following a Single Dose of Intravenous Colistimethate Sodium in Critically Ill Neonates
2
Issued Date
2016-11-01
Resource Type
ISSN
15320987
08913668
08913668
Other identifier(s)
2-s2.0-84973375144
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pediatric Infectious Disease Journal. Vol.35, No.11 (2016), 1211-1214
Suggested Citation
Narongsak Nakwan, Siripa Usaha, Kulkanya Chokephaibulkit, Paola Villani, Mario Regazzi, Roberto Imberti Pharmacokinetics of Colistin Following a Single Dose of Intravenous Colistimethate Sodium in Critically Ill Neonates. Pediatric Infectious Disease Journal. Vol.35, No.11 (2016), 1211-1214. doi:10.1097/INF.0000000000001263 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/41012
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Pharmacokinetics of Colistin Following a Single Dose of Intravenous Colistimethate Sodium in Critically Ill Neonates
Other Contributor(s)
Abstract
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. In this study, we sought to evaluate the pharmacokinetics of colistin after intravenous administration of colistimethate sodium (CMS) in the critically ill neonates with Gram-negative bacterial infections. A single intravenous dose of CMS [approximately 150,000 IU/kg, equivalent to 5 mg/kg colistin base activity (CBA)] was administered to 7 critically ill neonates. Mean (±SD) maximum plasma colistin concentration and area under the time-concentration curve from 0 to infinity were 3.0 ± 0.7 μg/mL and 25.3 ± 10.4 μg·h/mL, respectively. Time to maximum concentration, half-life, apparent volume of distribution and clearance were 1.3 ± 0.9 hours, 9.0 ± 6.5 hours, 7.7 ± 9.3 L/kg and 0.6 ± 0.3 L/h/kg, respectively. After a dose regimen of 5 mg/kg CBA every 24 hours, the average concentration expected at steady state is 1.1 ± 0.4 μg/mL. In critically ill neonates, a single intravenous dose of 5 mg CBA/kg (approximately 150,000 IU/kg of CMS) resulted in suboptimal plasma concentrations of colistin. According to our pharmacokinetics data, the dosage of CMS currently used in critically ill neonates is insufficient.